E156 Micro-Paper · Africa Clinical Trials

Biomarker Endpoint Quality

Biomarker-driven trials enable precision medicine and faster drug development, b...

Africa Trials
195
US Trials
11,919
Gap Ratio
61x
Nations
54
Key Finding
Africa hosts 23,873 trials across 54 nations with extreme geographic concentration.
Regional Comparison
Burden vs Investment 2000 4000 6000 8000 10000 50000 100000 150000 Africa US Europe
Biomarker Endpoint Quality by Country Egypt: 11752 Algeria: N/A Morocco: 162 Tunisia: 540 Senegal: N/A Ghana: 261 Nigeria: 379 Cameroon: N/A DRC: N/A Ethiopia: 302 Kenya: 788 Uganda: 809 Tanzania: 460 Rwanda: N/A South Africa: 3654 Egy 11752 Sou 3654 Uga 809 Ken 788 Tun 540 162 11752
Distribution Analysis
Regional Comparison Africa US Europe 0 5000 10000 15000
Contribution Breakdown 11752 Egypt 3654 South Afri 809 Uganda 788 Kenya 540 Tunisia 2814 Others
Inequality Profile
Enrollment Distribution Africa Reference 5000 10000
Research Profile Volume Growth Phase3 Complete Diversity
Temporal & Structural
No data
Phase Distribution Africa US Europe Phase 1 12 114.2 59.4 Phase 2 26 334.7 248.0 Phase 3 51 507.8 416.9 Phase 4 3 44.3 13.7 507.8 3
Why It Matters

Biomarker-driven trials enable precision medicine and faster drug development, but Africa's limited laboratory infrastructure constrains biomarker endpoint adoption.

The Evidence   133 words · target 156
In the methodological architecture of African clinical research, does the pattern of biomarker endpoint quality reveal structural inequity in African research investment? This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.gov through April 2026. Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation. Africa registered 195 relevant trials compared to 11,919 in the United States, revealing an 61-fold absolute gap in research volume. Temporal analysis showed 17.1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted. These results indicate that methodological capacity gaps limit the quality and impact of African clinical research output. Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.
Sentence Structure
Question

In the methodological architecture of African clinical research, does the pattern of biomarker endpoint quality reveal structural inequity in African research investment?

Dataset

This cross-sectional audit evaluated 23,873 African and 190,644 United States interventional trials registered on ClinicalTrials.

Method

gov through April 2026.

Primary Result

Investigators computed the rate ratio comparing Africa to other regions as the primary estimand using registry metadata for each nation.

Robustness

Africa registered 195 relevant trials compared to 11,919 in the United States, revealing an 61-fold absolute gap in research volume.

Interpretation

Temporal analysis showed 17.

Boundary

1-fold growth in African trial registrations from 2000-2005 to 2021-2025, though the gap with high-income regions persisted.

Extra

These results indicate that methodological capacity gaps limit the quality and impact of African clinical research output.

Extra

Interpretation is constrained by missing sub-national data and the exclusion of observational studies from the analysis.

Back to Group Download Code (.py) GitHub